Galectin-1 in stable liver transplant recipients.

[1]  Y. Ding,et al.  Galectin‐1 Prolongs Survival of Mouse Liver Allografts From Flt3L‐Pretreated Donors , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  R. Lechler,et al.  Absence of Galectin‐1 accelerates CD8+ T cell‐mediated graft rejection , 2012, European journal of immunology.

[3]  Gaosi Xu,et al.  Immunological tolerance induced by galectin-1 in rat allogeneic renal transplantation. , 2010, International immunopharmacology.

[4]  G. Rabinovich,et al.  Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 , 2009, Nature Immunology.

[5]  D. San Segundo,et al.  Changes in the serum levels of interleukin‐17/interleukin‐23 during acute rejection in liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  G. Rabinovich,et al.  Galectin-1 Suppresses Autoimmune Retinal Disease by Promoting Concomitant Th2- and T Regulatory-Mediated Anti-Inflammatory Responses1 , 2006, The Journal of Immunology.

[7]  M. Territo,et al.  Amelioration of graft versus host disease by galectin-1. , 2003, Clinical immunology.

[8]  G. Rabinovich,et al.  Recombinant Galectin-1 and Its Genetic Delivery Suppress Collagen-Induced Arthritis via T Cell Apoptosis , 1999, The Journal of experimental medicine.

[9]  T. Bringman,et al.  Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis , 1990, Journal of Neuroimmunology.